Skip to main content
Fig. 2 | Biomaterials Research

Fig. 2

From: New opportunities for nanoparticles in cancer immunotherapy

Fig. 2

Schematic illustration of multifaceted immunomodulatory nanoliposome (tumosome)-based cancer immunotherapy. a Multifaceted tumosomes consist of tumor cell membrane proteins, as tumor-associated antigens; two immunostimulatory adjuvants (3-O-desacyl-4′-monophosphoryl lipid A [MPLA] and dimethyldioctadecylammonium bromide [DDA]), as pathogen characters; and helper lipids (1,2-dioleoyl-sn-glycero-3-phosphocholine [DOPC] and cholesterol). b Image-guided cancer immunotherapy. First, to determine the exact position of tumor-draining lymph nodes, near infrared (NIR) tracer (indocyanine green, ICG) is injected, Second, tumor-draining lymph nodes are identified using NIR optical imaging. Third, tumosomes are injected into the lymph node with the guidance of NIR imaging (reprinted with permission from Ref [54]; © 2017 Wiley-VCH)

Back to article page